8 January 2026
VBB advises Adjuvant Global Health Technologies on investment in Phoenix Biosciences
1 min read
VBB has advised private investment fund Adjuvant Global Health Technologies (Adjuvant) on its investment in Phoenix Biosciences.
In the context of the Belgian pre-pack bankruptcy procedure relating to the distressed Univercells group, new corporate vehicle Phoenix Biosciences has acquired certain assets of Univercells subsidiary Quantoom Biosciences, a full-stack RNA partner for mRNA- and saRNA-based vaccines and therapeutics.
Adjuvant was a shareholder in the Univercells group and, alongside fellow shareholders, has contributed to a capital raise for Phoenix Biosciences.
The VBB team comprised partner Caroline DAOUT, counsel Virginie Lescot and associate Jens Westerwoudt.
->
News & insights
5 min
read
read
Briefings
Alleged Anticompetitive Bundling of MS Treatment & Diagnostic – Italian Competition Authority Investigates Biogen
29 May 2026
10 min
read
read
Briefings
CJEU Rules that EU Member States Cannot Restrict Online Sale of Non-Prescription Medicinal Products to Single Subcategory on Public Health Grounds
26 May 2026
15 min
read
read
Briefings
Deckers v. Up & Running: English Court of Appeal confirms brands’ ability to control online sales without infringing competition law
21 May 2026
15 min
read
read
Briefings
EU Pharmaceutical Package | Part I – Regulatory Data & Market Protection, Orphan Market Exclusivity, Bolar Exemption and Antimicrobial Vouchers
20 May 2026
10 min
read
read
Briefings
Technology Transfer Agreements – New EU and UK Competition Law Frameworks
18 May 2026
3 min
read
read
Briefings
Belgian Competition Authority Orders AutoScout24 to Restore Data Portability to Competing Platform Subject to Penalty Payments
5 May 2026
1 min
read
read
Briefings
European Commission issues new draft merger control guidelines, launches public consultation
30 April 2026
1 min
read
read
Briefings
First CMA Consumer Fine Shows Commitment to Enforce New Regime
29 April 2026
